ArticleAdvances in therapyPublished
Teclistamab Plus Daratumumab Versus Standard Daratumumab-Based Proteasome Inhibitor Combinations for Relapsed/Refractory Multiple Myeloma: An Inverse Probability of Treatment Weighting Analysis
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Advances in therapy
- Published
- Topic
- Clinical care
- Subject terms
- Indirect Treatment Comparison; Inverse Probability Of Treatment Weighting; Relapsed Or Refractory Multiple Myeloma; Teclistamab And Daratumumab
- PubMed ID
- 42970164
- Added to directory
- Source checked